Synonym: superior vena cava syndrome
Obstruction of the superior vena cava (SVC) can be due to external pressure, involvement of the vessel by tumour tissue, or a blood clot obstructing the lumen. William Hunter first identified the condition in 1757 in a patient with syphilitic aortic aneurysm. Today, the most common cause is superior mediastinal pressure associated with lung cancer (up to 70%).
The SVC extends from the junction of the right and left innominate veins to the right atrium. It is surrounded by the sternum, trachea, right bronchus, aorta, pulmonary artery and the perihilar and paratracheal lymph nodes. All these are relatively rigid structures and as the SVC runs along the right side of the mediastinum this thin-walled low pressure vessel can get easily compressed. The SVC supplies venous drainage for the head, the neck, the upper extremities and the upper thorax. When obstructed, collateral routes are provided by four main pathways:
- The azygous venous system, which includes the azygous vein, the hemizygous vein and the connecting intercostal veins
- The internal mammary venous system plus tributaries and secondary communications to the superior and inferior epigastric veins
- The long thoracic venous system connection to the femoral veins
- The long thoracic venous system connection to the vertebral veins
- Primary bronchial carcinoma
- Lymphadenopathy due to lymphoma
- Constrictive pericarditis
- Chronic fibrotic mediastinitis
- Clot associated with indwelling catheter or pacemaker wires
- Localised infection
- Thyroid cancer
- Synovial cell carcinoma
- Retrosternal goitre
- Mediastinal fibrosis
- Thoracic aortic aneurysm
- Aortic aneurysm
In children the most common causes are:
American studies indicate that superior vena cava (SVC) obstruction develops in 5-10% of patients with a right-sided malignant intrathoracic mass lesion. One study of small-cell lung cancer patients found SVC obstruction in 87 patients out of 724 at the time of diagnosis. With increasing cardiovascular interventions, the incidence of benign causes is increasing. One study found that an intravascular device was the most common etiology in benign cases (22 of 31 cases), with fibrosing mediastinitis the second most common benign aetiology (6 cases).
Gender predilection reflects aetiology, with more males than females due to the prevalence of lung cancer. Malignant causes are more common in the 40-60 age group and benign causes in the 30-40 age group.
The onset may be gradual or acute, depending on how quickly the condition proceeds from partial to complete obstruction and the degree of development of a collateral circulation.
One study identified dyspnoea, cough and chest pain at rest as being the most prominent symptoms, particularly in patients with malignancy. Other symptoms can include neck and face swelling, arm swelling, dizziness, headache, disturbed vision, nausea, nasal stuffiness, stupor and syncope. Symptoms tend to be aggravated by postures which increase the venous pressure in the upper part of the body, such as bending over or lying down.
Signs may include:
- Dilated veins over the arms, neck and anterior chest wall
- Dilated veins over the abdomen if a collateral circulation has developed
- Oedema of the face and arms
- Stridor due to laryngeal oedema
- Reduced mental function due to cerebral oedema
- Congested veins of the anterior chest wall, and a flushed face
- Stupor and even coma
Signs may get more pronounced when the arms are lifted above the head.
Diagnosis may be made on clinical grounds in patients with overt symptoms and signs. However, in more subtle cases, further investigations are required.
- Chest X-ray: this may reveal a widened mediastinum or a mass on the right side of the chest.
- CT scanning: this shows more detail, particularly of surrounding structures such as the bronchi and vocal cords and may be necessary to guide more invasive investigative procedures . Various refinements exist, including the use of several detectors taking images in different planes. Injection of contrast media to highlight collateral circulation improves the sensitivity of CT scanning even further.
- Doppler scanning: Doppler flows correlate well with CT scanning and changes seen during the respiratory cycle can be used to evaluate the severity of obstruction and the effect of therapy.
- MRI scanning: this was thought to have some advantages but these have largely been cancelled out by the technological enhancement of CT. MRI also takes longer and is more expensive.
- Invasive contrast venography: this is useful in some cases, particularly prior to surgery.
- Radionuclide technetium-99m venography and gallium single-proton emission CT scanning: these are additional techniques which may be useful in some cases.
Most cases of superior vena cava (SVC) obstruction present before the primary cause is elucidated, and there has been some controversy as to whether treatment should be instituted before diagnostic procedures are carried out. Radiotherapy, for example, can destroy histologically useful material. However, the underlying pathology is usually easy to identify.
- In 68% of cases, sputum cytology results are diagnostic and biopsy of palpable supraclavicular nodes is positive in 87% of cases.
- Bronchoscopy has a 60% success rate, whilst there is 100% success rate with thoracotomy.
- Open biopsy is not usually needed. Cervical mediastinoscopy and anterior mediastinoscopy are usually effective in establishing a histological diagnosis and open biopsy is rarely needed.
- Ultrasound-guided biopsy of material adjacent to the SVC has been demonstrated to be a relatively safe procedure.
- Elevation of the head, and oxygen, may help to provide symptomatic relief.
- Corticosteroids and diuretics may be indicated in the emergency situation (eg reduced cardiac output, cerebral or laryngeal oedema) although evidence for their efficacy is lacking.
- Radiotherapy is indicated in some lung cancer cases. The use of radiotherapy in superior vena cava (SVC) obstruction before a diagnosis of malignancy has been established is controversial but may occasionally be justified if symptoms are rapidly deteriorating or there have been multiple attempts to obtain a tissue diagnosis without success.
- Chemotherapy may be indicated in chemosensitive tumours (eg small-cell lung cancer).
- Anticoagulation may be required in cases where venography has demonstrated central vein thrombosis, to prevent pulmonary embolism. It may also be indicated in central venous stenosis to prevent thrombosis. Randomised controlled trials are required to determine the exact role of anticoagulation and venography in this condition.
- Stenting and/or angioplasty (also known as endovascular surgery) is particularly hopeful in patients requiring long-term venous access (eg haemodialysis, total parenteral nutrition), or severe SVC obstruction symptoms. An increasing body of evidence suggests it should be considered as first-line treatment for all benign disease as it is as effective but even less invasive than angioplasty.
- Surgical bypass of the obstruction is technically difficult but may be indicated in some cases. There are no large trials comparing this approach with stenting in benign disease.
- Selected patients may benefit from resection of the blockage, and reconstruction.
- Stenting is useful in relieving obstruction and a NICE review concluded that it was more effective and produced a quicker response than chemotherapy or radiotherapy. Thrombolysis and angioplasty may also be indicated in individual patients.
- Reconstructive surgery is possible and may be assisted by the use of autologous tissue.
- Insertion of a prosthesis does not increase the overall mortality from SVC resection and is a feasible option where reconstructive surgery is not possible.
This depends on the underlying condition. 45% of patients with lymphoma and 10% of patients with bronchogenic carcinoma, who are given radiotherapy, live at least 30 months. The average survival rate of untreated patients and those not responding to treatment is thirty days.
Further reading & references
- Brock H; The Many Facets of Dr William Hunter Historical Sciences xxxii 1994
- Nickloes T, Mack L; Superior Vena Cava Syndrome, eMedicine.com, 2009.
- Diagram of Superior Vena Cava; Healthopedia.com, 2009.
- Venous Collateral Circulation Head and Trunk; The Cardiothoracic Surgery Network 2007; Diagram
- Cumming M; Superior Vena Cava Syndrome, eMedicine.com 2008.
- Arya LS, Narain S, Tomar S, et al; Superior vena cava syndrome. Indian J Pediatr. 2002 Apr;69(4):293-7.
- Urban T, Lebeau B, Chastang C, et al; Superior vena cava syndrome in small-cell lung cancer. Arch Intern Med. 1993 Feb 8;153(3):384-7.
- Rice TW, Rodriguez RM, Light RW; The superior vena cava syndrome: clinical characteristics and evolving etiology. Medicine (Baltimore). 2006 Jan;85(1):37-42.
- Eren S, Karaman A, Okur A; The superior vena cava syndrome caused by malignant disease. Imaging with multi-detector row CT. Eur J Radiol. 2006 Jul;59(1):93-103. Epub 2006 Feb 14.
- SVC Case History; home.flash.net 2007; CT scan plates
- Lv FQ, Duan YY, Yuan LJ, et al; Doppler superior vena cava flow evolution and respiratory variation in superior Echocardiography. 2008 Apr;25(4):360-5.
- Khimji T, Zeiss J; MRI versus CT and US in the evaluation of a patient presenting with superior vena cava syndrome. Case report. Clin Imaging. 1992 Oct-Dec;16(4):269-71.
- Adegboye VO, Ogunseyinde AO, Obajimi MO, et al; Superior vena cava obstruction: diagnosis, management and outcome. East Afr Med J. 2008 Mar;85(3):129-36.
- Bagheri R, Rahim M, Rezaeetalab F, et al; Malignant superior vena cava syndrome: is this a medical emergency? Ann Thorac Cardiovasc Surg. 2009 Apr;15(2):89-92.
- Koegelenberg CF, Bolliger CT, Plekker D, et al; Diagnostic yield and safety of ultrasound-assisted biopsies in superior vena cava Eur Respir J. 2009 Jun;33(6):1389-95. Epub 2009 Feb 12.
- Rizvi AZ, Kalra M, Bjarnason H, et al; Benign superior vena cava syndrome: stenting is now the first line of treatment. J Vasc Surg. 2008 Feb;47(2):372-80.
- Lanuti M, De Delva PE, Gaissert HA, et al; Review of superior vena cava resection in the management of benign disease and Ann Thorac Surg. 2009 Aug;88(2):392-7.
- Stent placement for vena caval obstruction, NICE (2004)
- Wada N, Masudo K, Hirakawa S, et al; Superior vena cava (SVC) reconstruction using autologous tissue in two cases of World J Surg Oncol. 2009 Oct 13;7:75.
- Leo F, Bellini R, Conti B, et al; Superior vena cava resection in thoracic malignancies: does prosthetic Eur J Cardiothorac Surg. 2009 Nov 23.
|Original Author: Dr Laurence Knott||Current Version: Dr Laurence Knott|
|Last Checked: 19/02/2010||Document ID: 2825 Version: 23||© EMIS|
Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. EMIS has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.